Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
IN

NASDAQ · INAB

IN8bio, Inc.

Healthcare · Biotechnology

$0.93

Down-$0.02 (-2.02%)

Updated Nov 5, 2026, 7:13 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.02M
P/E ratio
-0.38
Dividend yield
0.00%
52-week range
$0.87 – $2.11
Volume
107.58K
Avg. volume
68.88K

Price performance · INAB

INAB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

INAB closed at $0.93 after 21 trading sessions, down 33.52% for the selected period.

Last close
$0.93
Period change
-33.52%
Period low
$0.90
Period high
$1.40
Daily close
View OHLC price history
INAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.94$0.97$0.92$0.9307107.58K
Nov 3, 2026$0.9605$0.9999$0.9499$0.949920.36K
Nov 2, 2026$0.9277$1.00$0.91$0.919.33K
Oct 30, 2026$0.96$0.979$0.9001$0.901347.94K
Oct 29, 2026$1.0101$1.0101$0.9801$0.98011.42K
Oct 28, 2026$1.0051$1.05$0.98$1.0213.22K
Oct 27, 2026$0.95$0.9908$0.9306$0.9612.2K
Oct 26, 2026$1.03$1.04$0.87$0.9655183.55K
Oct 23, 2026$1.02$1.0791$1.0181$1.0510.3K
Oct 22, 2026$1.06$1.0899$0.9758$0.985944.14K
Oct 21, 2026$1.16$1.16$1.0501$1.0932.21K
Oct 20, 2026$1.10$1.175$1.10$1.142.38K
Oct 19, 2026$1.11$1.1741$1.07$1.0921.75K
Oct 16, 2026$1.17$1.18$1.06$1.1131.73K
Oct 15, 2026$1.2088$1.235$1.17$1.1859.83K
Oct 14, 2026$1.185$1.23$1.135$1.2073.61K
Oct 13, 2026$1.25$1.26$1.18$1.1864.71K
Oct 12, 2026$1.3585$1.36$1.225$1.2339.32K
Oct 9, 2026$1.36$1.38$1.34$1.3413.05K
Oct 8, 2026$1.40$1.40$1.33$1.3822.32K
Oct 7, 2026$1.38$1.41$1.36$1.4020.69K

Latest INAB news

The latest Smart Investors Daily articles mentioning INAB.

Stock researchCompany · Overview

INAB research

Overview

Company profile and research snapshot.

Company profile

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
INAB recent ratings
DateFirmRatingTarget
Mar 13, 2026HC Wainwright & Co.Buy—
Mar 14, 2025HC Wainwright & Co.Buy—
Feb 12, 2025HC Wainwright & Co.Buy—
Feb 11, 2025Jones TradingBuy—
Nov 26, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 6, 2026

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 60,000 shares of its common stock. The award was approved by the Compensation Committee of the

Yahoo · Sep 22, 2026

IN8bio to Present at Sidoti Small-Cap Virtual Conference

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company

Yahoo · Sep 10, 2026

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York. Mr. Ho and members of the IN8bio management team will

Yahoo · Sep 9, 2026

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By